"Golden moments" for Gyrus as it bucks dollar trend
This article was originally published in Clinica
In spite of the preponderance of US dollar-denominated sales in its revenues mix, UK-based minimally invasive surgery products company Gyrus saw its first-half 2004 sales rise by 14% (26% on a constant exchange rate basis) to £42.5m ($75.7m). Profit before tax and goodwill amortisation was also up strongly, by 23%, at £3.7m, providing leverage on the sales growth and prompting executive chairman Brian Steer to talk of "major achievements" and of the "strength of the business model".
You may also be interested in...
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.